ARTICLE | Company News
Sanofi, U.S. Department of Health and Human Services infectious news
October 3, 2016 7:00 AM UTC
HHS’s Biomedical Advanced Research and Development Authority (BARDA) will grant Sanofi and its Sanofi Pasteur S.A. vaccines unit $43.2 million to conduct a Phase II trial of a purified inactivated Zika vaccine. Sanofi Pasteur expects the Phase II trial to begin in early 2018. BARDA may also opt to continue funding the vaccine's development through Phase III testing. ...